Seroatlas · Human Serome Atlas

CRKL

Crk-like protein

Also known as: CRKL_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: P46109
Gene: CRKL
Ensembl: ENSG00000099942
Chromosome: 22
Canonical length: 303 aa
Protein class: Plasma proteins, Predicted intracellular proteins
Subcellular location: Nucleoplasm,Cytosol

OverviewNCBI Gene

This gene encodes a protein kinase containing SH2 and SH3 (src homology) domains which has been shown to activate the RAS and JUN kinase signaling pathways and transform fibroblasts in a RAS-dependent fashion. It is a substrate of the BCR-ABL tyrosine kinase, plays a role in fibroblast transformation by BCR-ABL, and may be oncogenic.[provided by RefSeq, Jan 2009]

Canonical amino-acid sequenceUniProt

303 residues, UniProt reviewed canonical sequence.

>P46109|CRKL
     1  MSSARFDSSD RSAWYMGPVS RQEAQTRLQG QRHGMFLVRD SSTCPGDYVL SVSENSRVSH
    61  YIINSLPNRR FKIGDQEFDH LPALLEFYKI HYLDTTTLIE PAPRYPSPPM GSVSAPNLPT
   121  AEDNLEYVRT LYDFPGNDAE DLPFKKGEIL VIIEKPEEQW WSARNKDGRV GMIPVPYVEK
   181  LVRSSPHGKH GNRNSNSYGI PEPAHAYAQP QTTTPLPAVS GSPGAAITPL PSTQNGPVFA
   241  KAIQKRVPCA YDKTALALEV GDIVKVTRMN INGQWEGEVN GRKGLFPFTH VKIFDPQNPD
   301  ENE

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against CRKL can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Cell surface
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.42
Highest tissue expression: 51 nTPM

Expression across tissuesHPA

Tissue

skeletal muscle: 51 nTPM
bone marrow: 51 nTPM
tongue: 40 nTPM
thymus: 31 nTPM
cerebellum: 30 nTPM
cerebral cortex: 30 nTPM

Single-cell type

platelets: 89 nCPM
late spermatids: 73 nCPM
neutrophils: 70 nCPM
extravillous trophoblasts: 68 nCPM
esophageal apical cells: 64 nCPM
megakaryocytes: 56 nCPM

Immune cell

non-classical monocyte: 26 nTPM
eosinophil: 22 nTPM
total PBMC: 21 nTPM
naive CD4 T-cell: 20 nTPM
MAIT T-cell: 19 nTPM
naive CD8 T-cell: 19 nTPM

Brain region

thalamus: 71 nTPM
spinal cord: 71 nTPM
midbrain: 67 nTPM
medulla oblongata: 66 nTPM
white matter: 62 nTPM
cerebral cortex: 62 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.64
gnomAD pLI: 0.45
gnomAD missense Z: 1.94
DepMap mean gene effect: -0.93
DepMap dependency class: common

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 6% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of CRKL in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads CRKL as an antibody target. Whether an autoantibody or antibody against CRKL could matter depends on whether native CRKL is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

CRKL is annotated at the cell surface, where native CRKL is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label CRKL as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...